In this research study, the investigators aim to test the usability and efficacy of the GaitBetter system for gait rehabilitation after stroke.
This study consists of 3 distinct aims: In Aim 1, the investigators will evaluate clinical acceptance of the GaitBetter solution by subjects and therapists. To do so, the investigators will run a pilot study to gather feedback from stakeholders (not reported here). In Aim 2, the investigators will evaluate the efficacy of using the GaitBetter solution to improve motor-cognitive function of chronic stroke survivors. To do so, the investigators will run a single-arm, non-randomized study to test the hypothesis that the GaitBetter training is effective in improving gait and cognition in individuals with chronic stroke. In Aim 3, the investigators will explore the efficacy of using the GaitBetter solution for improving rehabilitation outcomes in sub-acute stroke survivors. To do so, the investigators will run a randomized, controlled study to evaluate the effects of using the GaitBetter system in patients with subacute stroke on recovery trajectory.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
76
Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes.
Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes. In addition, the investigators will record the number and duration of therapy sessions followed by the participant during standard of care.
Participants will follow their standard of care. The investigators will record the number and duration of therapy sessions followed during standard of care.
Spaulding Rehabilitation Hospital Boston
Boston, Massachusetts, United States
RECRUITING10 meter walk test (in chronic stroke survivors, Aim 2)
Evaluation of gait speed of chronic stroke survivors, in meters per second
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
10 meter walk test (in subacute stroke survivors, Aim 3)
Evaluation of gait speed of subacute stroke survivors, in meters per second
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Trail making test (in chronic stroke survivors, Aim 2)
Evaluation of cognition status, in chronic stroke survivors. The test record the time to accomplish the task (higher values indicate slower performance)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Trail making test (in subacute stroke survivors, Aim 3)
Evaluation of cognition status, in subacute stroke survivors. The test record the time to accomplish the task (higher values indicate slower performance)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Balance Evaluation Systems Test (mini-BESTest, in chronic stroke survivors, Aim 2)
Comprehensive evaluation of balance and falls risks in chronic stroke survivors. Score from 0 to 108. Higher scores are reflecting better balance
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Aim 3: Balance Evaluation Systems Test (mini-BESTest, in subacute stroke survivors, Aim 3)
Comprehensive evaluation of balance and falls risks in subacute stroke survivors. Score from 0 to108. Higher scores are reflecting better balance
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Step length (in chronic stroke survivors, Aim 2)
Evaluation of gait step length in chronic stroke survivors with an 3D motion capture system (in meters)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Step length (in subacute stroke survivors, Aim 3)
Evaluation of gait step length in subacute stroke survivors with an 3D motion capture system (in meters)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Step width (in chronic stroke survivors, Aim 2)
Evaluation of gait step width in chronic stroke survivors with an 3D motion capture system (in meters)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Step width (in subacute stroke survivors, Aim 3)
Evaluation of gait step width in subacute stroke survivors with an 3D motion capture system (in meters)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Step symmetry (in chronic stroke survivors, Aim 2)
Evaluation of gait step symmetry in chronic stroke survivors with an 3D motion capture system (ratio between paretic and non-paretic leg)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Step symmetry (in subacute stroke survivors, Aim 3)
Evaluation of gait step symmetry in subacute stroke survivors with an 3D motion capture system (ratio between paretic and non-paretic leg)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Stance time (in chronic stroke survivors, Aim 2)
Evaluation of gait stance time in chronic stroke survivors with an 3D motion capture system (in seconds)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Stance time (in subacute stroke survivors, Aim 3)
Evaluation of gait stance time in subacute stroke survivors with an 3D motion capture system (in seconds)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Swing time (in chronic stroke survivors, Aim 2)
Evaluation of gait swing time in chronic stroke survivors with an 3D motion capture system (in seconds)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)
Swing time (in subacute stroke survivors, Aim 3)
Evaluation of gait swing time in subacute stroke survivors with an 3D motion capture system (in seconds)
Time frame: Change from baseline scores at post-intervention (after 5 weeks)